Climate Change Data

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Climate Impact & Sustainability Data (2016, 2023)

Reporting Period: 2016

Environmental Metrics

Total Carbon Emissions:750,000 tons CO2 (estimated)
Water Consumption:8,769,376 m3/year
Waste Generated:80,848.14 tons/year

ESG Focus Areas

  • Product Quality
  • Healthcare Service Quality
  • Resources Conservation and Recycling
  • Staff Occupational Health and Safety Management
  • Remuneration and Welfare
  • Career Development of Employees
  • Innovation
  • Internationalization
  • Social Responsibility

Environmental Achievements

  • Energy consumption intensity decreased by 19.2% year-on-year.
  • Water consumption intensity decreased by 24.1% year-on-year.
  • 563,100 tons of water recycled internally.
  • Annual energy savings were over RMB7.00 million.

Social Achievements

  • Organized over 500 recreational and sports activities for employees.
  • Completed over 35 charitable donations.
  • Healthcare service subsidiaries held over 90 public health seminars and health consultations.
  • Average customer satisfaction rating of healthcare service member enterprises over 92%.

Governance Achievements

  • Improved corporate governance structure and internal management.
  • Established a CSR leading group and task force.
  • Implemented a comprehensive CSR management system.
  • Received various awards for corporate social responsibility and investor relations.

Climate Goals & Targets

Long-term Goals:
  • Dedicate to becoming a first-tier enterprise in the global healthcare market.
Medium-term Goals:
  • A Chinese pharmaceutical company with global competitiveness.
Short-term Goals:
  • A leading pharmaceutical company in China that advances in internationalization.

Environmental Challenges

  • Maintaining high quality standards across all subsidiaries and products.
  • Balancing rapid growth with sustainable development.
  • Managing environmental impacts of operations.
  • Ensuring compliance with laws and regulations.
Mitigation Strategies
  • Implemented strict quality control systems and EHS management systems.
  • Integrated CSR strategy into all business segments.
  • Increased investment in environmental protection facilities and emission reduction projects.
  • Established a comprehensive compliance and honest system.

Supply Chain Management

Supplier Audits: 58 supplier audits

Responsible Procurement
  • Established supplier management system
  • Implemented green supply chain project
  • Conducted credit checking on suppliers

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: GB/T 36000, GRI G4, ESG Reporting Guide under Listing Rules (Stock Exchange)

Certifications: ISO 14001, OHSAS 18001, ISO 15189, WHO-PQ

Third-party Assurance: SGS

Awards & Recognition

  • Best Social Responsibility Brand Award
  • Golden Bee • Leadership Enterprises Award
  • Responsibility Innovation Best Case Award for the Year
  • Excellent Enterprise Award of “Corporate Social Responsibility of Listed Companies”

Reporting Period: 2023

Environmental Metrics

Total Carbon Emissions:960,864 tCO2e/year
Scope 1 Emissions:210,819 tCO2e/year
Scope 2 Emissions:677,874 tCO2e/year
Scope 3 Emissions:72,171 tCO2e/year
Total Energy Consumption:7,748,179 GJ/year
Water Consumption:10,489,189 m3/year
Waste Generated:56,029 tons/year
Carbon Intensity:0.23 ton/RMB10,000 revenue

ESG Focus Areas

  • Environmental protection
  • Social responsibility
  • Corporate governance

Environmental Achievements

  • Reduced comprehensive energy consumption intensity by 1.35% year-on-year.
  • Reduced carbon emissions by 10,114 tons through energy-saving measures.
  • Purchased green electricity of 14,699,769 kWh, reducing carbon emissions by 8,383 tons.
  • Achieved the carbon emission intensity target for 2023.
  • Achieved the comprehensive energy consumption intensity target for 2023.
  • Achieved the sewage discharge intensity target for 2023.
  • Achieved the COD emission intensity target for 2023.
  • Achieved the total waste intensity target for 2023.
  • Achieved the hazardous waste intensity target for 2023.
  • Reduced hazardous waste landfill volume by 21% year-on-year.

Social Achievements

  • Launched the “Payment by Efficacy Value Plan” for Yi Kai Da®, reducing patients’ financial burden.
  • Yi Kai Da® successfully treated more than 600 LBCL patients in China.
  • Established more than 160 Yi Kai Da® qualified treatment centers.
  • Yi Kai Da® was included in the urban customized commercial supplementary insurance in more than 100 provinces and municipalities and 75 commercial insurances.
  • Launched various recruitment programs and attracted talents.
  • Carried out four series of training programs, providing employees with a comprehensive platform for improving their capabilities and skills.
  • Issued the “Employee Diversity Policy” and implemented an equal pay policy.
  • Employee turnover rate decreased by 2.93 percentage points compared to last year.
  • Provided various in-house training and development programs for employees.
  • Launched the program of “Caring for Women’s Health — Pink Blue Ribbon Charity Tour”, expanding the screening coverage for breast cancer and cervical cancer among women in Xishuangbanna, Yunnan.

Governance Achievements

  • Established a three-tier ESG governance structure.
  • Incorporated ESG sustainable development indicators into the performance assessment for senior management.
  • Established the Carbon Neutrality Committee.
  • Improved internal control and risk management systems.
  • Established an integrity management system and reporting channels to protect whistleblowers.
  • Provided employees with anti-corruption and business ethics training.
  • Conducted more than 50 audits, covering key processes such as R&D, sales, procurement and expenses.

Climate Goals & Targets

Short-term Goals:
  • Reduce water consumption intensity by 15% compared to 2020 by 2025.
  • Reduce carbon emission intensity by 15% compared to 2020 by 2025.

Environmental Challenges

  • Climate change risks (physical risks: rising average temperatures, frequent occurrence of extreme weather; transition risks: increased pricing of greenhouse gas emissions, requirements and regulation of the existing products and services).
  • Supply chain disruptions.
Mitigation Strategies
  • Formulated a comprehensive risk management strategy against climate change.
  • Invested RMB13.476 million in various energy-saving and emission reduction measures.
  • Improved energy utilization efficiency, adjusted energy structure, and promoted renewable energy.
  • Promoted multi-sourcing and localization of core materials to support product stability.

Supply Chain Management

Supplier Audits: 1,114 suppliers audited in 2023; 23 green supply chain audits.

Responsible Procurement
  • Supplier Code of Conduct
  • Anti-Commercial Bribery Agreement
  • Supplier Quality Requirements
  • Green supply chain audits

Climate-Related Risks & Opportunities

Physical Risks
  • Rising average temperatures
  • Frequent occurrence of extreme weather
Transition Risks
  • Increased pricing of greenhouse gas emissions
  • Requirements and regulation of existing products and services

Reporting Standards

Frameworks Used: GRI Standards 2021, Hong Kong Stock Exchange’s Environmental, Social and Governance Reporting Guide

Certifications: ISO 14001, ISO 45001, ISO 50001, ISO 9001, ISO/IEC 17025, ISO 13485:2016

Third-party Assurance: SGS

UN Sustainable Development Goals

  • Goal 3: Good Health and Well-being
  • Goal 7: Affordable and Clean Energy
  • Goal 9: Industry, Innovation and Infrastructure
  • Goal 10: Reduced Inequalities
  • Goal 13: Climate Action

Initiatives contribute to these goals through drug accessibility, renewable energy use, R&D innovation, fair pricing policies, and climate change mitigation.

Sustainable Products & Innovation

  • New generation of Pei Jin®
  • Yi Xin Tan®
  • Bei Wen®
  • Argesun®

Awards & Recognition

  • 2023 MSCI ESG A Rating
  • 2023 Top 30 ESG Excellence Practices
  • 2023 Outstanding Responsible Company
  • 2023 Most Admired Chinese Companies
  • 2023 Emerging Awarded Enterprise of China’s Excellence Management Company
  • 2023 Top 25 Global Pharmaceutical Companies in R&D Pipeline Size
  • 2023 Rank 1 in China’s Biopharmaceutical R&D Strength
  • 2023 Rank 2 in China’s Comprehensive Drug R&D Strength
  • 2022 CSR Report 5-Star Excellence